SCHEMBL3309953

SCHEMBL3309953

COc1ccc(CN2CCCCCC=CCCC(C(=O)O)NC(=O)C3CC(Oc4cc(-c5ccccc5)nc(OC)n4)C[N+]3C2=O)cc1

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CTSB P07858 1/20 0.33
▸ TDP1 Q9NUW8 2/20 0.33
▸ BCHE P06276 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ ACP1 P24666 2/20 0.32
▸ POLB P06746 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ FFAR2 O15552 1/20 0.31
▸ KCNH2 Q12809 5/20 0.31
▸ MCHR1 Q99705 4/20 0.31
▸ KDM1A O60341 1/20 0.31
▸ VCP P55072 1/20 0.31
▸ MMP1 P03956 1/20 0.30
▸ MMP13 P45452 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3314022 0.94 ALDH1A1 (0.32) CTSBTDP1BCHEMEN1HTT
SCHEMBL3308959 0.90 KCNH2 (0.36) MEN1HTTKMT2ASMN1; SMN2NPSR1
SCHEMBL3308918 0.84 MCHR1 (0.35) MEN1HTTKMT2ASMN1; SMN2NPSR1
SCHEMBL995145 0.80 MMP1 (0.34) MEN1KMT2AMMP1MMP13
SCHEMBL3552292 0.76 FAAH (0.31) —
SCHEMBL2839916 0.76 ALDH1A1 (0.33) NPSR1KCNH2MCHR1
SCHEMBL3315190 0.76 CTSB (0.45) CTSBTDP1MEN1KMT2ANPSR1
SCHEMBL3309948 0.76 CTSB (0.45) CTSBMEN1KMT2APOLBRAB9A
SCHEMBL3283641 0.73 CTSB (0.44) CTSBTDP1HTTSMN1; SMN2POLB
SCHEMBL3526341 0.73 ALDH1A1 (0.34) KMT2APOLBRAB9AKCNH2MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2118091-B1 PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS JANSSEN SCIENCES IRELAND UC (IE) 2015-04-15 — — EP disclosed
US-8937080-B2 Pyrimidine substituted macrocyclic HCV inhibitors MEDIVIR AB (SE) 2015-01-20 — — US disclosed
US-20100113440-A1 PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS TIBOTEC PHARMACEUTICALS, LTD. (IE) 2010-05-06 — — US disclosed
EP-2118091-A1 PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS Tibotec Pharmaceuticals (IE) 2009-11-18 — — EP disclosed
WO-2008095999-A1 PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS TIBOTEC PHARMACEUTICALS LTD. (IE) 2008-08-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113440-A1 PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS NUDT1, PNP, SLC28A1 CTSB 2141/4885TDP1 2560/4885BCHE 4492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback